Trial Profile

Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fondaparinux sodium (Primary)
Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
Focus Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

02 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
04 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com